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This review deals with the clinical, basic and genetic aspects of
a recently highlighted form of idiopathic ventricular fibrillation
known as the Brugada syndrome. Our primary objective in this
review is to identify the full scope of the syndrome and attempt to
correlate the electrocardiographic manifestations of the Brugada
syndrome with cellular and ionic heterogeneity known to exist
within the heart under normal and pathophysiologic conditions so
as to identify the cellular basis and thus potential diagnostic and
therapeutic approaches. The available data suggest that the
Brugada syndrome is a primary electrical disease resulting in
abnormal electrophysiologic activity in right ventricular epicar-
dium. Recent genetic data linking the Brugada syndrome to an ion
channel gene mutation (SCN5A) provides further support for the
hypothesis. The electrocardiographic manifestations of the Bru-
gada syndrome show transient normalization in many patients,
but can be unmasked using sodium channel blockers such as
flecainide, ajmaline or procainamide, thus identifying patients at
risk. The available data suggest that loss of the action potential
dome in right ventricular epicardium but not endocardium un-
derlies the ST segment elevation seen in the Brugada syndrome
and that electrical heterogeneity within right ventricular epicar-
dium leads to the development of closely coupled premature
ventricular contractions via a phase 2 reentrant mechanism that
then precipitates ventricular tachycardia/ventricular fibrillation
(VT/VF). Currently, implantable cardiac defibrillator implanta-
tion is the only proven effective therapy in preventing sudden
death in patients with the Brugada syndrome and is indicated in
symptomatic patients and should be considered in asymptomatic
patients in whom VT/VF is inducible at time of electrophysiologic
study.
(J Am Coll Cardiol 1999;33:5–15)
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In the United States alone, sudden death due to cardiac arrest
occurs with an incidence of more than 300,000 per year (1).
Recent interest has focused on unexpected arrhythmogenic
death occurring in individuals with minimal or no structural
heart disease, estimated to represent 3% to 9% of out-of-
hospital cases of ventricular fibrillation unrelated to myocar-
dial infarction (2). In addition to the ventricular preexcitation
syndrome and the long QT syndrome, a new electrocardio-
graphic (ECG) marker of sudden death in otherwise healthy
individuals has been identified. Referred to as the Brugada
syndrome, clinical cases have been reported in countries
worldwide (3–53). World Wide Web Home Page for the
Brugada syndrome has been introduced on the Internet (54).
The Brugada syndrome is characterized by a) a peculiar ST
segment elevation in the right precordial leads often accom-
panied by apparent conduction block in the right ventricle, b)
structurally normal heart and c) a propensity for life-
threatening ventricular tachyarrhythmias. Originally described
by Pedro and Josep Brugada as “right bundle branch block and
persistent ST segment elevation in V1–V3” in patients with no
apparent structural heart disease, this ECG abnormality and
its role in malignant arrhythmogenicity has become the subject
of increasing attention and controversy. Transient forms of the
disease in which the ECG manifestations normalize for a
period of time have been described more recently
(17,19,40,41,43). The prevalence of ventricular fibrillation
(VF) associated with this ECG phenomenon have been esti-
mated in some countries as high as 40% to 60% of all cases of
idiopathic VF (55). Certain electrophysiologic similarities have
been found between ECG markers of the Brugada syndrome,
early repolarization syndrome (56–58) and hypothermia (59–
62). A strong link has been identified between the Brugada
syndrome and sudden and unexpected death syndrome in
Southeast Asian men (17,29,24). Possible overlap with arrhyth-
mogenic right ventricular dysplasia (ARVD) and apoptosis has
been suggested (7–9,11,33), although the Brugada syndrome
and ARVD appear to be caused by defects in different
chromosomal loci. An ion channel defect resulting in hetero-
geneous loss of the action potential dome in right ventricular
epicardium has been proposed as a mechanism underlying
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both idiopathic ST segment elevation in the right precordial
leads and the dispersion of repolarization that predisposes the
heart to the development of malignant reentrant ventricular
arrhythmias (59–61). Recent genetic data linking the Brugada
syndrome to an ion channel gene mutation provides further
support for the hypothesis that the Brugada syndrome is a
primary electrical disease (55).
Our primary objective in this review is to identify the full
scope of this syndrome and attempt to correlate the electro-
cardiographic manifestations of the Brugada syndrome with
cellular and ionic heterogeneity known to exist within the heart
under normal and pathologic conditions so as to identify the
cellular basis and thus potential diagnostic and therapeutic
approaches.
Electrocardiographic Markers of the
Brugada Syndrome
In 1991–1992 Pedro and Josep Brugada described eight
otherwise healthy patients with sudden and aborted cardiac
death, in whom they found “right bundle branch block and
persistent ST segment elevation in leads V1–V3” (3,4). Based
on those clinical cases they outlined a new “distinct clinical and
electrocardiographic syndrome,” which has subsequently been
called the Brugada syndrome.
The electrocardiographic pattern of ST segment elevation
and inversion of the T wave in the right precordial leads with
and without right bundle branch block (RBBB) have been
described in apparently healthy individuals since 1953 (63–67).
This striking ECG phenomenon had been largely ignored until
Martini et al. (7) and Aihara et al. (24) brought attention to a
possible link between this ventricular repolarization abnormal-
ity and sudden death in their patients.
The QRS complex in the Brugada syndrome ends with a
positive deflection (or prominent J wave) followed by an
elevated down-sloping ST segment and a negative T wave with
a normal (38) or even short (24) QT interval. Leads V1 to V3
show the most prominent changes, with the degree of ST
segment elevation tapering off in adjacent leads and often
associated with varying degrees of conduction block in the
right bundle branch. In lead V1, the terminal portion of the
QRS complex is elevated as an r9 or a J wave followed by a
down-sloping ST segment ending in a negative deflection. In
adjacent leads the changes may be similar, but often the ST
segment elevation is more horizontal and less prominent. It is
a characteristic finding that the ST segment elevation in the
right precordial leads is not accompanied by reciprocal ST
segment depression in opposite leads (Fig. 1A). Repolarization
abnormalities are often more prominent in the right chest
leads placed on intercostal space higher than usual (42).
Clinicians have identified this “bizarre, extremely special form
of ST segment elevation” (13) as: a) major (coved type or
dome shape), b) minor (saddle-back type) and c) triangular
(31). Whereas a) is related to acute episodes of electrical
instability, b) is thought to be due to a chronic course of the
disease (47).
ST segment elevation in the right chest leads is observed in
a variety of clinical and experimental settings (Table 1) and is
not unique or highly specific for the Brugada syndrome. A
clear distinction cannot be made on the basis of an ECG alone.
However, ST segment elevation in the right precordial leads in
the absence of ischemia, electrolyte or metabolic disorders,
pulmonary or inflammatory diseases or abnormalities of cen-
tral or peripheral nervous system may identify the Brugada
syndrome. In such cases, the term “idiopathic” is appropriate.
The prevalence of idiopathic ST segment elevation is
reported to be 2.1% to 2.65% (14). An elevated ST segment
limited to the right precordial leads occurs in less than 1% of
all cases of elevated ST segment (68). The combination of ST
segment elevation in these leads and RBBB was found in 12
out of 22,027 subjects in Japan (0.05%). All 12 individuals were
male with no structural heart disease; four had a history of
sudden cardiac death (39). Sixty-three patients (60 male) with
RBBB, persistent ST segment elevation and a normal QT
interval are currently being followed in 34 medical centers in
Japan. So far, 12 have experienced episodes of syncope and 17
suffered ventricular fibrillation (35,47).
In many patients with the Brugada syndrome, the ECG
manifestations transiently normalize (40,41,43), leading to
underdiagnosis of the syndrome (38). Strong sodium channel
blockade using agents such as procainamide, ajmaline and
flecainide can unmask the ST segment elevation in V1–V3 and
right bundle branch block-like pattern in many patients (61). A
number of other agents, including adrenergic and cholinergic
neurohormones, are capable of modulating the degree of ST
segment elevation in Brugada syndrome patients. Beta-
adrenoreceptor stimulation and alpha-adrenoreceptor block-
ade reduce the magnitude of ST segment elevation, but not
necessarily the degree of conduction delay in the right ventricle
in patients with the Brugada syndrome, whereas beta-
adrenergic blockade, alpha-adrenergic stimulation, sodium
channel blockade and muscarinic stimulation augment the ST
segment elevations (29,42,50). More prominent ST segment
elevation in the right chest leads (but not RBBB) has been
observed immediately before (49,70) (Fig. 1B) and after
Abbreviations and Acronyms
ARVD 5 arrhythmogenic right ventricular dysplasia
ECG 5 electrocardiographic
ERS 5 early repolarization syndrome
ICa 5 calcium current
ICD 5 implantable cardiac defibrillator
IK-ATP 5 adenosine triphosphate–sensitive potassium current
INa 5 sodium current
Ito 5 transient outward current
RBBB 5 right bundle branch block
SUDS 5 sudden and unexplained death syndrome
TdP 5 Torsade de Pointes
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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episodes of aborted sudden cardiac death in some patients
(29,35).
The role of RBBB in the Brugada syndrome has been a
matter of some controversy. In surveying 80 published ECGs
obtained from patients with the Brugada syndrome, we found
that at least one third of those classified as RBBB did not meet
the ECG criteria for RBBB. Kasanuki et al., using body-
surface mapping, demonstrated a conduction delay in the
anterior wall and RV outflow tract in six patients with the
Brugada syndrome, only when a secondary R wave was present
in lead V1 (29). Prolongation of the H-V interval has been
documented in many clinical cases (4,15,28,50). However,
there appears to be no correlation between RBBB and sudden
cardiac death (69), whereas a definite link exists between the
magnitude of ST segment elevation and incidence of the
life-threatening arrhythmic events in patients with the Brugada
syndrome. Thus, conduction delay in the right ventricle may be
associated with the Brugada syndrome, but does not appear to
be an integral part of the syndrome.
Brugada Syndrome and Early Repolarization
Syndrome
Early repolarization syndrome (ERS), although character-
ized by idiopathic ST segment elevation, is different from the
Brugada syndrome in that it is generally not associated with
arrhythmias.
Electrocardiographically, both syndromes resemble a pat-
tern of reversed Wolff–Parkinson–White syndrome with dis-
tinct slur or notch on the downstroke of the R wave. However,
the elevated ST segment in ERS can be differentiated from ST
segment elevation in the Brugada syndrome by its localization
and pattern. The elevated ST segment in ERS is usually
localized in leads V2 to V4 (5) and has an upward concavity
with positive T wave polarity accompanied by a notched J point
(71), whereas ST segment elevation in the Brugada syndrome
is limited to the right precordial leads, is slowly down-sloping
and is followed by a negative T wave.
Electrophysiologically, ERS and the Brugada syndrome
share some common mechanisms of drug- and neuromodula-
Figure 1. (A) Twelve-lead electrocardiogram of a patient with the
Brugada syndrome. The right precordial leads, V1 to V3, display a
down-sloping ST segment elevation. QRS is normal but QT dispersion
between V2 and V6 is larger than normal (120 ms). (B) Self-
terminating polymorphic ventricular tachycardia (continuous record-
ing) in a patient with the Brugada syndrome. Closely coupled prema-
ture ventricular contractions precede the onset of tachyarrhythmia.
Note the disappearance of the repolarization abnormalities following
the arrhythmia.
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tion. As with the Brugada syndrome, isoproterenol is known to
reduce or even eliminate the ST segment elevation in individ-
uals with ERS, whereas propranolol increases the magnitude
of ST segment elevation (56).
Interestingly, ERS-like isoproterenol-sensitive ST segment
elevation often appears on ECGs of patients with high (cervi-
cal) spinal cord injury (C5 to C6). In contrast to patients with
lower spinal cord injury, injury to the cervical cord may
completely disrupt cardiac sympathetic influence from higher
centers, whereas parasympathetic control remains intact, sug-
gesting that inadequate sympathetic tone in the presence of
parasympathetic control of the heart may play a role in
generation of the ST segment elevation (72). This observation
was confirmed in experiments with spinal cord compression in
cats (73) and monkeys (74).
Brugada Syndrome and Sudden and
Unexpected Death Syndrome
Sudden and unexpected death of young adults during sleep
is endemic to Japan and Southeast Asia. The incidence of
sudden and unexpected death syndrome (SUDS) among
Asians living in the USA varies among different ethnic groups
from 1:2,500 to 1:1,087 (19,75,76). SUDS characteristics in-
clude the following: 1) victims are relatively young healthy men
leading normal lives; 2) death often occurs during sleep late at
night, and 3) autopsy findings are usually negative (77).
Aihara et al. were the first to focus attention on elevation of
the ST segment in the right chest leads in patients with
life-threatening ventricular tachyarrhythmias occurring at
night or during early morning hours (24). Nademanee et al.
identified this ECG phenomenon in the majority of SUDS
patients from Thailand; 17 out of 27 victims of either aborted
sudden death or syncope (or seizure) had a dynamic pattern of
ST segment elevation in precordial leads V1 to V3, often
accompanied by apparent conduction block in the right ven-
tricle. All were young men with a strong family history of
unexpected and unexplained death. In all, electrophysiologic
workup revealed a positive signal averaged ECG and inducible
polymorphic ventricular tachycardia (VT)/VF, although in
most echocardiography, coronary angiography, ventriculogra-
phy and magnetic resonance imaging revealed no evidence of
structural disease. Moreover, exercise normalized the ECG,
suggesting that the sympathetic nervous system plays an im-
portant role in modulation of this ECG phenomenon (17,19).
Brugada Syndrome and Arrhythmogenic
Right Ventricular Dysplasia
The nature of the primary defect in the Brugada syndrome,
whether cardiac or extracardiac, structural or functional, has
also been a topic of debate. It has been suggested that the
Brugada syndrome may represent either: a) a functional
abnormality of the electrical activity of the heart or a primary
electrical disease (34,37,38,59,60); or b) an early subclinical
manifestation of right ventricular dysplasia/cardiomyopathy
(2,7–9,33).
Some investigators report remarkable myocardial atrophy
with adipose tissue or fibrofatty infiltration in the dilated right
ventricle (often involving the conducting tissue), consistent
with ARVD, in all of their patients with the Brugada syn-
drome, whereas others report no structural defects whatsoever
in any patient with the same syndrome. In this regard, it is
important to emphasize that at the present time we do not have
a gold standard for clinical or histologic diagnosis of ARVD.
There is no controlled study that examines either the sensitivity
or specificity of postmortem findings, quantitative evaluation
of the fatty infiltration or the degree of fibrotic tissue involve-
ment (37).
The Brugada syndrome, like ARVD, is also consistent with
autosomal dominant inheritance with variable expression (22).
However, it is not related to any gene abnormality so far
described for ARVD (78,79). It seems premature to draw any
definitive conclusions as to whether the Brugada syndrome is
or is not an atypical or early manifestation of the ARVD.
It is intriguing to speculate that the Brugada syndrome may
start out as a primary electrical disease, but chronically
progress to develop structural abnormalities. This hypothesis is
suggested by the observation that electrical remodeling in
atrial fibrillation and ventricular hibernation precedes struc-
tural remodeling (80).
Table 1. Abnormalities That Can Lead to ST Segment Elevation in
the Right Precordial Leads
In the Clinic:
Right or left bundle branch block, left ventricular hypertrophy (66,108)
Acute myocardial infarction (109)
Left ventricular aneurysm (109)
Exercise test–induced (110)
Acute myocarditis (111)
Right ventricular infarction (112)
Dissecting aortic aneurysm (113)
Acute pulmonary thromboemboli (114)
Various central and autonomic nervous system abnormalities (115,116)
Heterocylic antidepressant overdose (117)
Duchenne muscular dystrophy (118)
Friedreich ataxia (119)
Thiamine deficiency (120)
Hypercalcemia (121)
Hyperkalemia (108,122)
Compression of the right ventricular outflow tract by metastatic tumor (123)
Cocaine intoxication (124)
In Experimental models:
Isolated sheets of canine ventricular epicardium exposed to potassium
channel openers, sodium and calcium channel blockers, acetylcholine,
metabolic inhibition and ischemia (59–61,89–103)
Injection of potassium salts into blood perfusing the coronary arteries (125)
or into subepicardium (126,127)
Potassium chloride application on the pericardial surface (128)
Right ventricular infarction (129)
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Diagnostic Workup
Programmed electrical stimulation reproducibility induces
VT or VF in almost all Brugada syndrome patients with a
history of aborted sudden death or syncope. Positive late
potentials on signal-averaged ECG are a common finding as
well, particularly in patients in whom an elevated ST segment
is accompanied by apparent RBBB. Because the ECG mani-
festations of the syndrome are often transient, the use of
sodium channel blocking agents including ajmaline, procain-
amide and flecainide to unmask the syndrome is recommended
in those in whom the syndrome is suspected (81). Imaging
techniques, endocardial biopsy and cardiac catheterization are
useful in ruling out structural cardiac abnormalities. Finally,
extension of the testing to family members is also important
(38) because of high incidence of familial occurrence (82).
Clinical Course and Current Concepts of the
Treatment Strategy
The mean age of affected individuals is in the mid to late
thirties, ranging from 4 to 70 years. All clinical manifestations
of the Brugada syndrome are attributed exclusively to the
life-threatening ventricular tachyarrhythmias and their compli-
cations. Tragically, in some patients sudden death is the first
and only clinical event. Diagnosis and prevention of life-
threatening ventricular tachyarrhythmias and their complica-
tions are the main objective of therapy.
In the majority of cases, malignant tachyarrhythmias occur
at rest and in many cases at nighttime, especially in Japan and
Southeastern Asia. A sudden rise in vagal activity has been
reported to occur just before VF episodes in some patients
(29), whereas abnormally high sympathetic tone has been
documented in other patients 1 week after episodes of VF (51).
In some patients mental stress (18) and alcohol consumption
(15) are thought to be provocative factors.
The incidence of arrhythmic events is similar in patients
receiving either an implantable cardiac defibrillator (ICD),
amiodarone or beta-adrenergic blocking agents. However, only
patients with an ICD are protected from sudden death (29,82).
The first randomized clinical trial of defibrillator versus treat-
ment with beta-blockers was initiated in 1997 (17). A cardio-
selective blocker of transient outward current (Ito), although
not available in today’s pharmacologic armamentarium, is
expected to be highly effective in protecting patients with the
Brugada syndrome against VT/VF (61,81,83). Antiarrhythmic
agents with Ito blocking properties, such as quinidine, may also
prove effective (2,81).
Thus, at present there are no specific pharmacologic treat-
ments for preventing sudden death in patients with the Bru-
gada syndrome. Implantation of an ICD is the only effective
intervention for preventing sudden death. Of special interest
are individuals displaying the ECG features of the Brugada
syndrome, but without arrhythmogenic complications. Their
potential risk of sudden death should be evaluated during
electrophysiologic study; inducibility of VT/VF should be
considered as an indication for an ICD (82).
Possible Cellular and Ionic Mechanisms
ST segment elevation and phase 2 reentry. A down-sloping
ST segment elevation similar to that observed in the Brugada
syndrome is a normal characteristic of the ECG of some
rodents (84). This manifestation of the ECG is due to a
much earlier repolarization of the epicardial action poten-
tial due to a more intense Ito (85). Accordingly, block of Ito
with 4-aminopyridine normalizes the Accent Potential Dura-
tion (APD) of rat/mouse epicardium and endocardium, yield-
ing an isoelectric ST segment (86–88).
An isoelectric ST segment is a normal feature of the ECG
in higher mammals. This is due to the fact that the voltage of
the early part of phase 2 of the action potential is relatively
similar throughout the myocardium, due to the development of
a prominent calcium current (ICa)-mediated action potential
plateau. The development of a normal plateau phase is depen-
dent on the balance of currents active at the end of phase 1;
usually this balance is predominantly inward due to a strong
ICa and relatively weak toward currents such as Ito. Under
pathophysiologic conditions, the balance of current active at
the end of phase 1 can shift outward, causing a loss of the
action potential dome. This occurs when the contribution of
inward currents at the end of phase 1 is relatively weak and
that of the outward currents is relatively strong. Pathophysio-
logic conditions (e.g., ischemia, metabolic inhibition) and some
pharmacologic interventions (e.g., sodium current [INa] or ICa
blocking agents or adenosine triphosphate–sensitive potassium
current [IK-ATP] activators) are capable of causing a marked
abbreviation of the action potential in canine and feline
ventricular epicardial cells, where Ito is prominent, but not
endocardial cells. Under these conditions, the ECG displays an
ST segment elevation similar to that observed in patients with
the Brugada syndrome.
Most of the characterization of this phenomenon and its
arrhythmic sequelae is the result of work conducted in the
canine heart (59–61,89–103). The presence of a prominent
Ito-mediated notch predisposes canine ventricular epicardium
to all-or-none repolarization and phase 2 reentry. Under
ischemic conditions and in response to a variety of drugs,
including sodium and calcium channel blocking agents, canine
ventricular epicardium exhibits an all-or-none repolarization
as a result of the rebalancing of currents flowing at the end of
phase 1 of the action potential. Failure of the dome to develop
occurs when the outward currents (principally Ito) overwhelm
the inward currents (chiefly ICa), resulting in a marked (40% to
70%) abbreviation of the action potential (59–61,89–103).
Under these conditions the action potential plateau (dome) is
usually abolished at some epicardial sites but not others,
causing a marked dispersion of repolarization. Propagation of
the action potential dome from sites at which it is maintained
to sites at which it is abolished can cause local reexcitation of
the preparation. This mechanism, termed phase 2 reentry,
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produces closely coupled extrasystolic beats, which can then
initiate one or more cycles of circus movement reentry (92)
(Figs. 2 and 3). Under ischemic conditions (Figs. 2 and 3) the
contribution of ICa is reduced, thus shifting the balance of
current at the end of phase 1 to net outward in canine
epicardium (92). Similar electrical heterogeneity leading to
phase 2 reentry occurs in canine epicardium exposed to: a) K1
channel openers such as pinacidil (96); b) sodium channel
blockers such as flecainide (97); c) increased [Ca21]o (95), and
d) metabolic inhibition (100). Because the level of Ito is pivotal,
Ito block restores electrical homogeneity and abolishes reen-
trant activity in all cases (Fig. 3).
Phase 2 reentry as a trigger for idiopathic ventricular
fibrillation. As already discussed, loss of the action potential
dome (plateau) in epicardium but not endocardium would be
expected to cause elevation of the ST segment, similar to that
found in patients with the Brugada syndrome (98,100). Be-
cause loss of the dome is caused by an outward shift in the
balance of currents active at the end of phase 1 of the action
potential (principally Ito and ICa), autonomic neurotransmit-
ters like acetylcholine facilitate loss of the action potential
dome (101) by suppressing calcium current and augmenting
potassium current, whereas beta-adrenergic agonists such as
isoproterenol and dobutamine restore the dome by augment-
ing ICa. Sodium channel blockers also facilitate loss of the
canine right ventricular action potential dome as a result of a
negative shift in the voltage at which phase 1 begins (97,102).
Accentuation of the ST segment elevation in patients with
the Brugada syndrome following vagal maneuvers or sodium
channel blockers, as well as normalization of the ST elevation
following beta-adrenergic agents are concordant with the
findings in isolated tissue preparations (50,60). The appear-
ance of the ST segment elevation only in right precordial leads
in patients with the Brugada syndrome is also consistent with
the observation that loss of the action potential dome is much
more easily induced in right than left canine ventricular
epicardium (98,100) because of the higher density of Ito in
Figure 3. Phase 2 reentry-initiated circus movement tachycardia abol-
ished with transient outward current inhibition. (A) Exposure of canine
right ventricular epicardial sheet to simulated ischemia results in loss
of the dome at sites 3 and 4 but not at sites 1 and 2 (basic cycle
length 5 1100 ms). Conduction of the basic beat proceeds normally
from the stimulation site (site 2; see schematic a). Propagation of the
action potential dome from the right half of the preparation causes
reexcitation of the left half via a phase 2 reentry mechanism (see
schematic b). The extrasystolic beat generated by phase 2 reentry then
initiates a run of tachycardia that is sustained for four additional cycles
via a typical (phase 0) circus movement reentry mechanism. The
proposed reentrant path is shown in Schematic c. Note that phase 2
reentry provides an activation front roughly perpendicular to that of
the basic beat. (B) Recorded 5 min after addition of 1 mmol/L
4-aminopyridine (4-AP), an inhibitor of the transient outward current.
In the continued presence of ischemia, 4-AP restores the dome at all
epicardial recording sites within 3 min. Thus electrical homogeneity is
restored and all reentrant activity abolished. Adapted with permission
from Lukas and Antzelevitch (92).
Figure 2. Phase 2 reentry. Reentrant activity was induced by exposure
of a canine ventricular epicardial preparation to simulated ischemia.
Microelectrode recordings were obtained from four sites as shown in
the schematic (upper right). After 35 min of ischemia, the action
potential dome develops normally at site 4, but not at sites 1, 2 or 3.
The dome then propagates in a clockwise direction, reexciting sites 3,
2 and 1 with progressive delays, thus generating a reentrant extrasys-
tole with a coupling interval of 156 ms at site 1. basic cycle length 5
700 ms. A similar phenomenon is observed upon exposure of right
ventricular epicardium to acetylcholine, potassium channel openers
and inhibitors of sodium and calcium inward currents. Adapted with
permission from Lukas and Antzelevitch (92).
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right than left ventricular epicardium (103,104). These similar-
ities in electrophysiology, pharmacology and ECG have
prompted us to speculate that a depressed right ventricular
epicardial action potential dome underlies the ST segment
elevation and that phase 2 reentry may provide the trigger for
episodes of ventricular fibrillation in patients with the Brugada
syndrome (81).
A test of these hypotheses has recently been performed in
arterially perfused canine right ventricular wedge preparations.
Preliminary results using the perfused wedge preparation
support the hypothesis that ST segment elevation in patients
with the Brugada syndrome may be the result of loss of the
action potential dome in right ventricular epicardium, where
Ito is most prominent, but not in endocardium, where Ito is
weak. Initiation of VT/VF under these conditions is via phase
2 reentry secondary to heterogeneous loss of the epicardial
action potential dome (59). The VT generated in these prep-
arations was sometimes polymorphic, resembling a rapid form
of Torsade de Pointes (TdP). This activity may be mecha-
nistically related to the migrating spiral wave shown by
Pertsov et al. (105) to generate a pattern resembling TdP
associated with a normal QT interval. Both in the perfused
wedge and in isolated tissues, agents that inhibit Ito, includ-
ing 4-aminopyridine, quinidine and disopyramide, proved
effective in restoring the action potential dome, thus restoring
electrical homogeneity and aborting all arrhythmic activity.
Thus class I antiarrhythmic agents that block INa much more
potently than Ito (procainamide, ajmaline and flecainide)
appear to unmask or exacerbate the ECG pattern of the
Brugada syndrome, whereas those with actions to block both
INa and Ito (quinidine and disopyramide) exert an ameliorative
effect.
For these concepts to be considered as applicable to
humans, it is important to demonstrate the presence of a large
Ito in human epicardium but not endocardium. Two separate
studies have shown these distinctions in myocytes isolated from
the respective regions of the human heart (106,107). An
important difference between man and dog is that Ito reacti-
vation is much faster in human epicardium than in the dog
epicardium, suggesting that electrical heterogeneity and phase
2 reentry might occur over a much wider range of heart rates
and be less influenced by heart rate in the human ventricle.
Candidate genes for the Brugada syndrome. One of the
easiest means to induce ST segment elevation and phase 2
reentry in isolated epicardial tissue preparations is through
block of the sodium channel. Sodium channel blockers facili-
tate loss of the canine right ventricular action potential dome
as a result of a negative shift in the voltage at which phase 1
begins (97,102). Gene mutations that diminish the density or
conductance of the sodium channel are therefore prime can-
didates. Such mutations would also be consistent with the
conduction disturbances that sometimes accompany the Bru-
gada syndrome. Based on the results discussed above, other
candidates include gene mutations that alter the intensity or
kinetics of either Ito or ICa so as to augment the activity of the
former and diminish that of the latter during the early phases
of the action potential. Genes of autonomic receptors that
modulate the activity or expression of these channels as well as
those that regulate IK-ATP are candidates as well.
The first gene to be linked to the Brugada syndrome was
reported in early 1998. Chen and colleagues in the laboratory
of Drs. Wang and Towbin studied six small families and two
sporadic cases of the Brugada syndrome using molecular
genetic methods. Based on the presumed pathophysiology
leading to the electrocardiographic findings, a candidate gene
approach was taken. A variety of ion channels were screened
for mutations and, in three families, mutations in the cardiac
sodium channel gene, SCN5A, the same gene responsible for
Figure 4. Cardiac sodium channel gene SCN5A missense mutation
cosegregating with the Brugada syndrome. (A) Electrocardiogram of
an affected individual. Note the elevated ST segment in leads V1 to V3.
(B) Pedigree structure and mutation analysis using single strand
conformation polymorphism analysis with primers amplifying exon 28
of the cardiac sodium channel gene, SCN5A. Affected individuals are
filled circles (female) and filled squares (male). Unaffected individuals
are empty symbols, and individuals without clinical data are shown as
hatched. The individual who suffered sudden cardiac death is slashed.
(C) Deoxyribonucleic acid and amino-acid sequences of the SCN5A
missense mutation associated with the Brugada syndrome. Deoxyribo-
nucleic acid sequence analysis revealed a C to T substitution, which
causes the substitution of a highly conserved threonine by a methio-
nine at codon 1,620 (T1620M mutation) in the extracellular loop
between DIVS3 and DIVS4. Adapted with permission from Chen et al.
(55).
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LQT3, were identified (Fig. 4) (55). It should be emphasized
that the mutations were at sites other than those known to
contribute to the LQT3 form of the long QT syndrome, and
the QT interval was not prolonged in these patients (Fig. 5).
The mutations encountered in the Brugada syndrome patients
caused either an acceleration of the recovery of the sodium
channel (missense mutation) or nonfunctional sodium chan-
nels (insertion and deletion mutations). Electrophysiologically
these mutations are thought to cause VF due to heterogeneity
of the refractory period caused by the presence of both normal
and mutated sodium channels in the same tissue (i.e., in the
case of the missense mutation) or by the reduction in the
number of functional sodium channels (as seen in the deletion
and insertion mutants), which as previously discussed would be
expected to promote the development of reentrant arrhyth-
mias.
SCN5A was excluded as the gene causing the Brugada
syndrome in at least one family, leading to the speculation that
genetic heterogeneity exists in the Brugada syndrome. These
findings provide further support for a primary electrical dis-
ease as the basis for the Brugada syndrome form of idiopathic
VT/VF.
Summary and Future Directions
The available data suggest that the Brugada syndrome is a
familial primary electrical disease caused by a defect in an ion
channel gene, resulting in premature repolarization of some
right ventricular epicardial sites. The resulting transmural
repolarization gradient underlies the phenotypic ST segment
elevation, and the intraepicardial dispersion of repolarization
gives rise to closely coupled phase 2 reentrant extrasystoles
that can precipitate VT/VF. Patients at risk often show peri-
odic normalization of the ST segment, leading to underestima-
tion of the syndrome. Sodium channel blockers can be used to
unmask the syndrome and should be avoided by Brugada
patients unless they also significantly block Ito. Implantable
cardiac defibrillator implantation is the only unequivocally
effective treatment and should be considered in symptomatic
and asymptomatic individuals with positive electrophysiologic
testing. These observations notwithstanding, our knowledge of
this and other idiopathic VF syndromes remains scant. Future
studies will be aimed at further genetic linkage analysis of large
families affected by the Brugada syndrome to examine the full
scope of the genetic basis for the disease as well as to assess
pharmacologic therapy using Ito blockers and other agents.
We are indebted to Drs. Pedro Brugada, Josep Brugada and Ramon Brugada for
their helpful comments. Our special appreciation for Dr. Yasuhiro Yokoyama
for helping with translation from Japanese.
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